The worldwide marine pharmaceutical pipeline consists of three FDA-approved drugs namely cytarabine, vidarabine, and ziconotide, whereas, the current clinical pipeline includes 13 marine-derived compounds that are either in Phase I, Phase II, or Phase III clinical trials.